What's new in IDIS:

 • New Drugs

 • Drug Name/Code Changes

 • FDA Approval Packages

 • Advisory Committee Meetings

 • Continuing Education Articles

 • Priority Clinical Practice Guidelines

 

 

IDIS Training Tools

 

Stay Connected:

 • IDIS on Facebook

 • Join Our Update Lists

 • CAMIPR

 • Monthly Update Information

 

 

Email: idis@uiowa.edu


Drug Information Resources

Notice: IDIS database discontinuation December 31, 2014.   Read more.

IDIS Logo   IDIS Monthly Update Information - March 2014

NEW DRUG TERM
ANATABINE
ATR-107
AV-0113
BECAPLERMIN
BECLABUVIR
BKT-140
CADAZOLID
DALANTERCEPT
IDO-5 PEPTIDE
IMETELSTAT
ISIS-SMN
ITX-5061
LEDIPASVIR
LEE-011
MK-3475
MK-7243
MORINIDAZOLE
NETUPITANT
NEUROKININ B
OLESOXIME
RILAPLADIB

CODE
95000612
82000593
10120645
82000012
8180136
14000096
8122961
14000521
10120646
10121067
14000727
8180137
8180135
44100118
10120312
80164005
8320033
56220041
14000119
92000411
24060107



DRUG NAME/CODE CHANGES

OLD TERM & CODE
CAT-354 82000538

NEW TERM & CODE
TRALOKINUMAB 82000538


FDA APPROVAL PACKAGES

Article Numbers 712725-712740: Dapagliflozin, Farxiga, FDA Approval Package for NDA 202293. FDA Approval Package 2014.

Article Numbers 712198-712213: Umeclidinium Bromide/Vilanterol Trifenatate, Anoro Ellipta, FDA Approval Package for NDA 203975. FDA Approval Package 2013.


ADVISORY COMMITTEE MEETINGS

Article Numbers 712803-712808: Nonprescription Drugs Advisory Committee Meeting, February 26, 2014. FDA Advisory Committee 2014.

Article Numbers 712796-712802: Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pulmonary-Allergy Drugs Advisory Committee, February 25, 2014. FDA Advisory Committee 2014.

Article Numbers 712789-712795: Cardiovascular and Renal Drugs Advisory Committee Meeting, February 12, 2014. FDA Advisory Committee 2014.

Article Numbers 712782-712788: Cardiovascular and Renal Drugs Advisory Committee Meeting, January 16, 2014. FDA Advisory Committee 2014.

Article Numbers 712775-712781: Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, February 10-11, 2014. FDA Advisory Committee 2014.

Article Numbers 712748-712754: Cardiovascular and Renal Drugs Advisory Committee Meeting, January 15, 2014. FDA Advisory Committee 2014.

Article Numbers 712741-712747: Cardiovascular and Renal Drugs Advisory Committee Meeting, January 14, 2014. FDA Advisory Committee 2014.

Article Numbers 712483-712491: Pediatric Oncologic Drugs Advisory Committee Meeting, November 5, 2013. FDA Advisory Committee 2013.

Article Numbers 712476-712859: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, December 12, 2013. FDA Advisory Committee 2013.

Article Numbers 712469-712475: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, December 11, 2013. FDA Advisory Committee 2013.

Article Numbers 712462-712468: Joint Meeting of the Gastrointestinal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, December 9, 2013. FDA Advisory Committee 2013.


CONTINUING EDUCATION ARTICLES

Article Number 712876: Anonymous. Macitentan (Opsumit) for Pulmonary Arterial Hypertension (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for Both Articles in this Issue, Article Numbers 712875 and 712876]. Med Lett Drugs Ther 2014, 56:15-16.

Article Number 712875: Anonymous. Dapagliflozin (Farxiga) for Type 2 Diabetes (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for Both Articles in this Issue, Article Numbers 712875 and 712876]. Med Lett Drugs Ther 2014, 56:13-15.

Article Number 712873: Anonymous. Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for These Articles in this Issue, Article Numbers 712872 and 712873]. Med Lett Drugs Ther 2014, 56:10-12.

Article Number 712872: Anonymous. Perampanel (Fycompa) for Epilepsy (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for These Articles in this Issue, Article Numbers 712872 and 712873]. Med Lett Drugs Ther 2014, 56:9-10.

Article Number 712870: Anonymous. Antiviral Drugs for Influenza 2013-2014 (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for These Articles in this Issue, Article Numbers 712869 and 712870]. Med Lett Drugs Ther 2014, 56:6-8.

Article Number 712869: Anonymous. Sofosbuvir (Sovaldi) for Chronic Hepatitis C (0.1 CEU) [IDIS Note: The 1.0 Hour of CE Credit is for These Articles in this Issue, Article Numbers 712869-712870]. Med Lett Drugs Ther 2014, 56:5-6.

Article Number 712769: Cada D J, Levien T L, Baker D E. Dolutegravir (0.15 CEU). Hosp Pharm 2014, 49:184-195.

Article Number 712627: Anonymous. Drugs for HIV Infection (0.2 CEU). Treat Guidel Med Lett 2014, 12:7-16.

Article Number 711541: Cada D J, Levien T L, Baker D E. Ferric Carboxymaltose (0.15 CEU). Hosp Pharm 2014, 49:52-69.


PRIORITY CLINICAL PRACTICE GUIDELINES

Article Number 712243: Bellmunt S, Alonso-Coello P. Cilostazol: Same Evidence, Different Conclusions (Ref Art 672868). Chest 2014, 145:435-436.

Article Number 711825: Schillie S, Murphy T V, Sawyer M, Ly K, Et Al. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR 2013, 62:1-19.


College of Pharmacy